Axon Enterprise has shifted from its roots as a TASER hardware provider to a broader public-safety technology platform that includes body cameras, cloud software, drones, robotics, and AI analytics. This integrated approach, where hardware serves as sensors feeding data into cloud systems, gives it an edge over narrower competitors because each new feature enhances the overall platform's stickiness. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Management sees the company as only about 15% penetrated in its core U.S. state and local market, with a total addressable market estimated at $159 billion to $160 billion. That gap points to ongoing opportunities for cross-selling and upselling. Software and services now represent the higher-margin, faster-growing segment, with ARR rising about 39% year over year and software growth outpacing hardware. The company's long-term goals of $6 billion in annual revenue and a 28% adjusted EBITDA margin by 2028 reflect an aim to grow profitably while continuing to invest in new capabilities.
Several factors could influence AXON stock performance in the quarters ahead. Earnings reports will stay in focus, especially after management lifted its full-year 2026 revenue growth forecast to 32%–34% on strength across public safety, international, federal, and enterprise channels. How well the company delivers on that outlook will be closely monitored.
The AI pipeline, featuring tools such as Draft One for automated reporting, Axon Assistant, Axon Vision, and the Axon Gravity data initiative, could drive broader adoption as agencies move beyond pilots. The counter-drone business, supported by the Safer Skies Act's $250 million in federal grants, adds policy support. Analyst notes show a generally positive stance, with firms like RBC Capital (Outperform, $860), Piper Sandler (Overweight, $893), and Morgan Stanley (Overweight) offering constructive views, while UBS remains more measured (Neutral, $610). Average price targets sit in the low-to-mid $800s.
Public-safety budgets tend to hold up reasonably well, though local spending can respond to tax collections and interest rates. Higher rates may increase financing costs for government purchases, while cooling inflation could ease pressure on component prices such as memory that have weighed on margins. Geopolitical and security issues have boosted interest in counter-drone and surveillance solutions, especially around events like the World Cup and Olympics. AI and automation trends also align with efforts to address staffing shortages in law enforcement. Regulatory attention on privacy, data security, and AI ethics remains a factor that could affect rollout speeds.
Looking ahead, international, federal, and enterprise expansion represents the largest growth runway beyond the established U.S. public-safety base. Managing the cost structure will be important as the company balances rapid scaling with margin goals, targeting EBITDA margin improvement by 2028. Shifts toward AI-enabled software and drone-as-first-responder programs should continue moving revenue toward higher-margin, recurring sources. Competition from players such as Motorola Solutions persists, and regulatory developments around AI and data governance could influence timelines. Capital allocation, including acquisitions like Fusus and Dedrone, indicates ongoing investment in growth areas. Consensus views remain generally constructive, with average price targets in the low-to-mid $800s, though execution and valuation will be key variables.
In my analysis of stocks like AXON, I occasionally turn to AI forecasting tools to supplement fundamental work. The Trend Prediction Engine stands out as a practical option for spotting potential bullish, bearish, or sideways moves over the next week or month. It offers searchable categories, historical context, and alert features that help evaluate developing trends and possible breakouts. Traders interested in layering AI signals onto their research may find it a helpful addition.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for AXON moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 270 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage biopharmaceutical company
Industry AerospaceDefense